Abstract The Toxicology Investigators Consortium (ToxIC) Case Registry was established by the American College of Medical Toxicology in 2010. The Registry contains data from participating sites with the agreement that all bedside medical toxicology consultations will be entered. Currently, 83% of accredited medical toxicology fellowship programs in the USA participate. The Registry continues to grow each year, and as of 31 December 2016, a new milestone was reached, with more than 50,000 cases reported since its inception. The objective of this seventh annual report is to summarize the Registry's 2016 data and activity with its additional 8529 cases. Cases were identified for inclusion in this report by a query of the ToxIC database for any case entered from 1 January to 31 December 2016. Detailed data was collected from these cases and aggregated to provide information which includes the following: demographics (age, gender, race, ethnicity, HIV status), reason for medical toxicology evaluation (intentional pharmaceutical exposure, envenomation, withdrawal from a substance), agent and agent class, clinical signs and symptoms (vital sign abnormalities, organ system dysfunction), treatments and antidotes administered, fatality and life support withdrawal data. Fifty percent of cases involved females, and adults aged 19-65 were the most commonly reported. There were 86 patients (1.0%) with HIV-positive status known. Non-opioid analgesics were the most commonly reported agent class, with acetaminophen the most common agent reported. There were 126 fatalities reported in 2016 (1.5% of cases). Major trends in demographics and exposure characteristics remained similar overall with past years' reports. While treatment interventions were commonly required, fatalities were rare.
Introduction
The Toxicology Investigators Consortium (ToxIC) was created by the American College of Medical Toxicology (ACMT) in 2010 as a tool for clinical toxicology research and toxicosurveillance [1] . Unlike other poisoning databases, ToxIC is a prospective case registry based on medical toxicologists' experience performing consultations in both inpatient and ambulatory settings. Cases where a formal consultation was not done, such as where advice was given over the telephone, are not included in the database.
The ToxIC Registry is unique in several important ways. Because all information was entered by treating medical toxicologists, the toxicological data reflects the best professional judgment of skilled clinicians. Much of the information on the database is not available from other sources and includes not only medical data but also demographics including race and ethnicity and HIV status.
In 2016, there was a 2.0% decrease in sites included in the ToxIC Registry, with four sites added and five withdrawn or dropped from participation because they withdrew or failed to meet quality standards set by the Registry. Two of the international sites were not included in 2016 due to withdrawal or lack of case entry. At the end of 2016, there were 46 sites, comprising 79 facilities with active case entry. Currently, 83% of active accredited medical toxicology fellowship programs in the USA participate in the ToxIC Registry. The objective of this report is to summarize the Registry's 2016 data and activity. Cases entered in 2016 are described in this seventh annual report.
Since its inception, several supplemental or subregistries have been created within ToxIC. These are designed to collect more detailed information in specific areas. Our subregistries studying caustic ingestions and prescription opioid abuse were closed at the end of 2016; data from these subregistries are now being analyzed. Subregistries on lipid resuscitation therapy, North American snake bites, and extracorporeal substance removal continued to collect data in 2016 and are continuing into 2017. Three additional subregistries were approved and developed in 2016 and became live on January 1, 2017; these include subregistries on plant, mushroom and herbal toxicity; pediatric opioid exposures; and pediatric marijuana exposures.
In 2016, 14 abstracts and five manuscripts using ToxIC Registry data were published and are listed on http://www. ToxICRegistry.org (Farrugia et al. [2] ; Beauchamp et al. [3] ; Judge et al. [4] ; Riederer et al. [5] ; Wang et al. [6] ).
In 2016, ToxIC was supported by a continuation of a grant from the US National Institutes of Health on cardiovascular drug toxicity, a new contract with the US Food and Drug Administration, and the continuation of unrestricted grant support from BTG International, which was used to support the North American Snakebite Registry.
Methods
A detailed description of the creation and design of the ToxIC Registry has been previously reported by Wax et al. [1] . To be part of the consortium, all medical toxicologists at participating institutions agree to enter data into the ToxIC Registry on all medical toxicology consultations performed. Cases are entered on a password-protected encrypted online data collection form. The site is maintained by ACMT with oversight by the ToxIC Leadership Group. The Registry is compliant with the Health Insurance Portability and Accountability Act (HIPAA) and does not collect any protected health information or otherwise identifying fields. Registry participation is pursuant to the participating institution's Institutional Review Board (IRB) approval and compliant with their policies and procedures. The Registry has also been independently reviewed by the Western IRB and determined not to meet the threshold of human subject research under federal regulation 45 CFR 46 and associated guidance.
Data collected on each case include presenting signs and symptoms, clinical course, treatments, limited patient demographics, outcome, laboratory values, and circumstances of and reasons for toxicological exposure. The term Bconsultation^is used in this report to describe any inperson encounter with a medical toxicologist in which a formal evaluation was conducted and placed in the medical record. Such encounters may include admission to a medical toxicology in-patient service, or evaluation by a medical toxicologist as a consulting physician in an emergency department, inpatient unit, or outpatient clinic. The online data collection form is formatted to ensure data entry remains organized and searchable. Free text entry fields allow providers to provide further detail or supplementary information. As part of the Registry's toxicosurveillance mission, one component of the standard data form is a sentinel detection field that signals novel or unusual cases. Analysis of novel exposure surveillance data in the Registry has begun, with results to be published in a separate report.
For this report, a search of the database was performed to identify cases recorded from January 1, 2016, through December 31, 2016. Additional data from the subregistries will be published separately. This descriptive report summarizes case demographics, source and location of consultation, and reasons for encounter, and provides case frequencies by individual agent class and treatment provided.
In the tables describing individual agents or agent classes, unless otherwise indicated, values with fewer than five occurrences were not listed as separate items but are further grouped as Bmiscellaneous.^Percentages noted in tables for individual agents represent their relative proportion within their respective agent class.
For clinical signs or symptoms, the tables provide the percentage of individual signs or symptoms relative to the total number of Registry cases in 2016. Signs and symptoms include the presence or absence of a toxidrome, vital sign abnormalities, and a variety of organ system-based derangements which may arise from a toxic exposure. For each subheading in the data collection instrument, investigators are required to either select an abnormality, or BNone,^to improve the accuracy of data collection. In the detailed treatment tables, percentages for each treatment modality represent the relative frequency among all treatments rendered.
Results
A total of 8529 cases were entered in the ToxIC Registry in 2016, up slightly from 8115 in 2015 (Fig. 1) [2] . Table 1 lists the individual sites entering cases in 2016.
Demographics
Selected demographics are summarized in Tables 2, 3 , 4, 5, 6, 7, and 8. In 2016, male (50.0%) and female (50.0%) cases were distributed evenly and 0.6% were pregnant. Adults age 19-65 years comprised the majority (67.0%) of cases, with children age 13-18 years the next most common (16.8%). There were a total of 2280 (26.7%) pediatric cases (0-18 years) overall. The most commonly reported race categories were Caucasian (58.1%) and black/African (14.1%), with 18.0% unknown/uncertain. Nine hundred fifty-one cases (11.2%) reported Hispanic ethnicity, while 19.1% reported ethnicity as unknown. Race and ethnicity are not self-reported in the Registry, and limitations in these data points continue to be addressed with ongoing quality improvement measures. Table 4 presents demographic data on the 86 HIV-positive patients (1.0%) reported in the Registry. Table 5 details the referral source of medical toxicology evaluations. Table 6 provides information on the type of exposure which prompted a medical toxicology encounter. More detailed information on the intent surrounding the intentional pharmaceutical exposures is provided in Table 7 . Table 8 depicts the frequency of common types of exposures as broken down by race, ethnicity, and gender. In all races, and for both Hispanics, nonHispanics, and both genders, intentional pharmaceutical exposures were more common than intentional nonpharmaceutical exposures.
Agent Classes
There were 11,352 individual agent entries in 2016 for 8529 reported cases with 2519 (29.5%) cases involving multiple agents. The top agent classes were the same as 2015 [2] , with non-opioid analgesics the most common (12.8%), followed by sedative-hypnotics/muscle relaxants (11.8%), antidepressants (11.1%), and opioids (9.8%) ( Table 9) . Tables 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 , and 26 show frequencies of individual agent entries by class, presented in order of most to least common class. Three agents-ethanol, lithium, and amphetamine-like hallucinogens-are their own classes but are reported with other agent classes (toxic alcohols, anticonvulsants and mood stabilizers, and psychoactives, respectively) for brevity. Tables S1-S18 in the Supplementary Material present frequencies for agent classes with little diversity, few overall cases, or when infrequently reported miscellaneous agents made up a significant portion of entries. Table 10 presents the non-opioid analgesics class. This has been the most frequently reported agent class since 2013 [2, 7, 8] . The most common agent was acetaminophen (67.9%), which was also the most common agent in the Registry overall, involved in 11.6% cases, consistent with previous years. Table 11 reports the sedative-hypnotics/muscle relaxants class. Benzodiazepines were the most frequently reported (52.6%) with alprazolam (20.6%), clonazepam (15.5%), and lorazepam (7.4%) the top three reported. In 2016, alprazolam eclipsed clonazepam as the most commonly reported benzodiazepine for the first time since the ToxIC Registry began [2, [7] [8] [9] [10] [11] . Other commonly reported agents in this class included the muscle relaxants cyclobenzaprine and baclofen, gabapentin (in the BOther sedatives^subclass), and zolpidem (in the BNon-benzodiazepine agonists^subclass). Barbiturates were infrequently mentioned, consistent with prior years. Table 12 presents the antidepressant class. Bupropion (in the BOther antidepressants^subclass) was the most frequently reported, comprising 20.7% of antidepressant cases and 3.0% of 2016 Registry cases overall, consistent with prior years. The selective serotonin reuptake inhibitors (SSRIs), particularly sertraline and fluoxetine, were the second most common subclass (34.3%), followed by the tricyclic antidepressants (TCAs) (15.1%) (e.g., amitriptyline), and the serotoninnorepinephrine reuptake inhibitors (SNRIs) (e.g., venlafaxine). Table 13 summarizes opioid frequencies, including naturally derived, synthetic, and semisynthetic agents. As in previous years, heroin was the most commonly reported (28.3%), followed by oxycodone (17.8%) and methadone (8.9%). Table 14 reports the sympathomimetic class. Cocaine was the most commonly reported (34.3%), followed by methamphetamine (25.7%) and amphetamine (12.4%), consistent with previous years. The pharmaceutical stimulants methylphenidate and lisdexamfetamine together accounted for 9.9% of the class. A number of designer stimulant drugs were reported, with methylenedioxy-N-methamphetamine the most common (4.3%). Less common designer agents, combined in the miscellaneous category, included the 2C series drugs, 25I-NBOMe, and other unspecified phenethylamines. Table 15 describes the anticholinergic and antihistamine class (Table 15) , and the most commonly reported agent was diphenhydramine (59.1%), which was also one of the most commonly reported agents in the Registry overall, involved in 4.9% of cases. Hydroxyzine was the next most common (14.9%), followed by other first-generation antihistamines chlorpheniramine and doxylamine. Second-generation antihistamines were reported less frequently. Table 16 presents frequencies for ethanol and the toxic alcohols. Ethanol was again the second most commonly reported agent overall in the Registry (N = 694), involved in 8.1% of cases. Among the toxic alcohols, ethylene glycol was the most common (45.5%), followed by isopropanol (32.5%), while methanol was less commonly reported (13.8%). Table 17 presents the cardiovascular agent class. The 654 cardiovascular agent entries comprised 5.8% of all Registry entries in 2016. In this class, beta adrenergic receptor antagonists (beta-blockers) were the most commonly reported (27.7%), followed by sympatholytics (25.8%), similar to prior years. Metoprolol was the most common beta-blocker. Clonidine (21.6%) was the most common sympatholytic reported with guanfacine also reported but to a much lower extent (4.3%). Together, the calcium channel antagonists comprised 17.3% of the agent class, with amlodipine the most common, followed by diltiazem and verapamil. Angiotensinconverting enzyme (ACE) inhibitors comprised only 8.0% of the cardiovascular agent mentions, with lisinopril accounting for >90% of these. Forty-six cardiac glycoside cases were reported, with all involving digoxin except for two digitoxin cases. Other subgroups of cardiovascular agents were less commonly reported. Table 18 summarizes the 642 antipsychotic agents reported, which accounted for 5.7% of all Registry entries in 2016. Consistent with prior years, quetiapine was by far the most commonly encountered antipsychotic agent. There were more than three times as many quetiapine cases reported (47.8%) as olanzapine (13.6%), the next most common agent. On its own, quetiapine was listed in 3.6% of all Registry cases in 2016. Aripiprazole was also frequently reported (8.1%), similar to past years. Risperidone, haloperidol, and clozapine together accounted for an additional 16.5% of the antipsychotic agent class. Table 19 shows anticonvulsants and mood stabilizers. Lithium is considered a unique agent class and reported separately in Table 19 . Lithium was reported in 176 cases, representing 2.1% of total Registry cases in 2016. Lamotrigine and valproic acid were the two most commonly reported agents in the anticonvulsants and mood stabilizers class. These were followed by phenytoin, carbamazepine, oxcarbazepine, and topiramate. Table 20 presents information on envenomations and marine poisonings. This class was dominated by snake envenomations in 2016, consistent with prior years. Crotalus spp. were the most commonly reported (34.1%), followed by Agkistrodon spp. (30.9%), and unspecified snakes (20.6%). Spider envenomations (e.g., Loxosceles spp., Latrodectus spp., and unspecified spider) were less common, together making up 9.0% of the class. Table 21 summarizes the psychoactive agent class, which includes marijuana and other cannabinoid receptor agonists, hallucinogens, and dissociatives. Synthetic cannabinoids were the most frequently entered (32.1%), followed by marijuana, lysergic acid diethylamide (LSD), phencyclidine, and gamma hydroxybutyrate. Amphetamine-like hallucinogens are reported with the psychoactives in Table 21 . Table 22 reports data on diabetic medications. Agent frequencies were similar to previous years, with metformin (41.0%) and insulin (24.8%) the most common. These were followed by the sulfonylurea agents: glipizide, glyburide, and glimepiride. Table 23 presents the metals agent class which was dominated by lead (30.3%), iron (20.7%), and mercury (13.8%), followed by chromium (7.6%) and cobalt (4.8%). The miscellaneous subclass, comprised of 13 different agents, accounted for 15.9% of entries. Table 24 presents the gases, irritants, vapors, and dusts class. Carbon monoxide was the predominant agent (43.2%), followed hydrogen sulfide (11.2%), and cyanide and smoke (16.8% combined). Table 25 reports household product exposures. Sodium hypochlorite ≤6% (household bleach) was the most common (31.3%), followed by other cleaning solutions and disinfectants (20.5%) and laundry detergent pods (13.3%). Caustic agents are described separately in Table S4 in the Supplemental Material. Table 26 presents the diverse species of the plants and fungi agent class. Consistent with prior years, unspecified mold and unknown mushrooms were the predominant agents, followed by Mitragyna speciosa (kratom), and a miscellaneous category containing 19 different plant and fungi agents.
Individual Agents by Class
Additional agent classes presented in the Supplementary Material include cough and cold products (Table S1) , herbal products and dietary supplements (Table S2) , hydrocarbons (Table S3) , caustics (Table S4) ; antimicrobials (Table S5) , other pharmaceutical products (Table S6) , other nonpharmaceutical products (Table S7) , anticoagulants (Table S8) , chemotherapeutic/immunological agents (Table S9) , pesticides, including herbicides, insecticides, rodenticides, and fungicides (Table S10) , endocrine agents (Table S11) , gastrointestinal agents (Table S12) , anesthetics (Table S13) , anti-parkinsonism drugs (Table S14) , pulmonary agents (Table S15) , weapons of mass destruction/riot/radiological agents (Table S16) , and ingested foreign bodies (Table S17) . Table 27 summarizes the 3134 clinical toxidromes reported in 2016. The frequencies of reported toxidromes were similar to past years with sedative-hypnotic the most common (14.9%), followed by anticholinergic (7.4%), sympathomimetic (4.5%), and opioid (4.4%). Table 28 summarizes the 2627 major vital sign abnormalities recorded in 2016. Tachycardia was the most common (12.1%), followed by hypotension (8.0%), bradycardia (4.6%), and several others affecting <4% of total cases. Note that some cases reported more than one major vital sign abnormality. Additionally, cases may include more than one of the other signs/symptom categories described below. Table 29 summarizes the neurological signs and symptoms reported in 2016. While the overall numbers of cases with neurological signs and symptoms increased from previous years, the order remained similar, with coma/central nervous system depression the most common (34.7%), followed by agitation (16.7%) and delirium (11.8%). Table 30 summarizes the cardiovascular and pulmonary signs and symptoms reported in 2016. Although the total number of cardiovascular and pulmonary signs reported was higher this year than in previous years, the order remained similar, with prolonged QTc (≥500ms) the most common cardiovascular sign (5.6%), followed by prolonged QRS (≥120 ms) (1.8%). The most common pulmonary sign was respiratory depression (11.1%). Table 31 summarizes signs and symptoms involving other organ systems. As in the past years, metabolic signs (e.g., elevated anion gap, metabolic acidosis) were common, reported in 12.2% of cases. Renal and musculoskeletal signs (e.g., rhabdomyolysis, acute kidney injury) were also common a I n c l u d e s 3 -m e t h y l f e n t a n y l , desomorphine, naloxone, pentazocine, propoxyphene, remifentanil, tapentadol, and U47700 (designer opioid) Table 32 including  cases involving single agent exposures and Table 33 including cases involving multiple agents. Table S18 in the Supplementary Information summarizes information on fatality cases with no suspected toxicologic exposure, or an unknown exposure(s). The number of fatalities increased again in 2016 to 126, along with an increased percentage of cases reporting a fatality (1.5%), up from 98 fatalities (1.2%) in 2015, and 89 fatalities (1.0%) in 2014 [2, 7] . Of these 126 fatalities, 63 (0.7%) Table S18 . Six fatalities (four females, two males) involved pediatric (age 0-18 year) patients. All six were adolescents, with ages ranging from 14 to 17 years, constituting 4.8% of fatalities. Five of these were intentional pharmaceutical exposures, with some intent to self-harm, and four were reported as definitive suicide attempts. An additional case reported toxicology involvement to assist with interpretation of lab data and evaluation of malicious or criminal intent. Three pediatric fatalities involved single agents (bupropion, cocaine, and diphenhydramine) and three involved multiple agents (acetaminophen, bupropion, ethanol, fluoxetine, ibuprofen, meclizine, and quetiapine). Life support measures were withdrawn in five of the six pediatric fatality cases. The sixth case is reported as unknown whether life support was withdrawn in a 16-year-old male with an exposure to acetaminophen and ethanol, and no treatment interventions are listed. This entry was categorized as misuse or abuse of a substance by taking higher doses than recommended of an over the counter product without an attempt at self-harm. No further details were provided to describe the lack of interventions or treatments recorded such as pronounced on arrival, or family or religious preference.
Clinical Signs and Symptoms
Among the single agent fatalities (all ages), there were four deaths attributed to ethanol; of these, three were intubated and mechanically ventilated and received either continuous renal replacement or hemodialysis. Eight single agent fatalities (age range 21-51 years) were attributed to heroin and one to fentanyl (a 19-year-old). Of the multiple agent fatalities, six involved heroin and three involved fentanyl. Fourteen fatalities overall were single a Includes Naja nigricinta, Vipera palaestinae, Micrurus spp., scorpion unspecified, and stingray Life support measures were withdrawn in 60 (61.2%) of the fatalities related to a toxicologic exposure (single or multiagent), with brain death confirmed in 26 (43.3%). The 60 patients ranged in age from 14 to 80 years (including 5 pediatric patients), with two patients of unknown age. The mean and median ages for those with life support withdrawn were 44.6 and 43.5 years, respectively, with a sex distribution of 55.0% male and 45.0% female.
Adverse Drug Reactions
Table 34 presents information on adverse drug reactions (ADRs). In 2016, there were 320 cases (3.8% of Registry cases) that were categorized as ADRs, defined as any unintended response to a medication as used in standard therapeutic dosing. There were 455 total agent entries with 164 unique agents. Some cases reported multiple agents, possibly reflecting drug-drug interactions. The strength of association between the reported agent and the clinical presentation was recorded as definitive by rechallenge in 4.7% of cases, probable in 72.8%, and possible in 22.5%. The most frequently recorded drugs in ADR cases in 2016 were lithium (11.9%) and digoxin (5.9%). Class total 80 (100) a I n c l u d e s a c o n i t u m , A g a s t a c h e scrophulariifolia (purple giant hyssop), Amanita muscaria, Brugmansia (angels trumpet), Convallaria majalis (lily of the valley), Crataegus (hawthorn), Datura inoxia (moonflower, thornapple), Dieffenbachia, Ganoderma mushroom, kola nut, kombucha tea, Nerium oleander, petasites (butterbur), Phytolacca a m e r i c a n a ( p o k e w e e d ) , P i p e r methysticum (kava), plants and fungi unspecified, poppy seeds (Papaver), Ricinus communis (castor beans), and Sanseviera (Snake plant, Mother in Laws tongue) (Table 35 ). Similar to prior years, Nacetylcysteine was the most common, accounting for more than one quarter of antidotes given in 2016 (27.5%), followed by naloxone/nalmefene (19.9%), and sodium bicarbonate (11.9%). In 2016, 2.7% of Registry cases reported antivenom therapy, with the vast majority of these (96.1%) receiving Crotalidae polyvalent immune fab (ovine), again reflecting the presence of the North American Snake Bite Registry within the overall Registry (Table 36) . Tables 37 and 38 , respectively, summarize the pharmacological and non-pharmacological supportive care intervention frequencies in 2016. A total of 3830 pharmacological and 4522 non-pharmacological supportive care interventions were reported. There were 2741 cases (32.1% of total Registry cases) reporting at least one form of pharmacologic treatment and 3508 cases (41.1% of total Registry cases) reporting at least one nonpharmacological intervention. Some cases involved more than one form of treatment. Similar to past years, benzodiazepines were used in half of the pharmacological interventions, followed by opioids (10.8%), vasopressors (10.3%), and antipsychotics (7.2%). Of the non-pharmacological interventions, intravenous fluid resuscitation was the most common (70.3%), followed by intubation and ventilatory management (25.1%). Table 39 summarizes the 31 chelation therapy interventions, which accounted for 0.4% of total Registry cases in 2016. Deferoxamine and dimercaptosuccinic acid (DMSA) were reported in equal numbers. Table 40 summarizes the 334 decontamination procedures reported in the Registry in 2016. There were 318 cases (3.7% of total Registry cases) in which at least one decontamination procedure was performed. Activated charcoal was most common (79.3%), followed by whole bowel irrigation (9.9%), and external irrigation (8.7%). Gastric lavage was uncommon with only seven cases (2.1%) reported. Table 41 reports enhanced elimination procedures. Enhanced elimination was performed in 280 cases (3.3% of total cases), with some cases reporting more than one, for a total of 321 reported treatments. Hemodialysis for toxin removal (32.1%) and urinary alkalinization (29.3%) were the most common. Hemodialysis for other indications comprised an additional 19.0% of enhanced elimination procedures. HR heart rate, BP blood pressure, RR respiratory rate a Percentage equals the number of cases relative to the total number of Registry cases in 2016 (N = 8259) b Total reflects cases reporting at least one major vital sign abnormality; cases may be associated with more than one major vital sign abnormality
Discussion
This report summarizes the seventh year of data collected in ACMT's ToxIC Case Registry. Although the Registry is not population based, it is a large source of information that can be used in conjunction with data from health agencies, poison centers, and other sources to produce a more detailed picture of poisoning trends and their public health implications. Novel exposure surveillance data from the Registry is not reported in this Annual Report, but is being analyzed, with results to be published separately. The most common agent classes, types of encounters, toxidromes, and treatments were similar to prior years. Some broad trends, both within the Registry itself and within the larger national context, are discussed.
Opioids
Opioid fatalities reported in the ToxIC Registry over the past few years mirror the national trends of steadily increasing age-adjusted death rates (per 100,000 population) from heroin and synthetic opioids other than methadone (e.g., fentanyl, tramadol) according to National Vital Statistics System data [12, 13] . In 2016, heroin-related deaths in ToxIC were the highest reported since the Registry's inception, increasing both in absolute number and in percentage of all fatalities cases-11.1% of fatalities in 2016 versus 4.1% in 2015 and 6.7% in 2014 [2, 7] . Fentanyl-related deaths also increased in 2016 with four reported cases (3.2%), up from 0.0% in 2015 and 1.1% in 2014 [2, 7] . The total number of opioid-related fatalities (all agents) in ToxIC increased to 29 cases (23.0% of total fatalities) in 2016, compared to 14.2% in 2015 and 18.0% in 2014 [2, 7] . Deaths related to illicit street opioid use may be more complicated to ascribe definitively to heroin or to fentanyl and newer fentanyl derivatives since testing for these agents is not routinely conducted. Thus, it is possible that some of the deaths attributed to heroin in the ToxIC Registry may be related to newer synthetic opioids. Of note, the number of ToxIC cases (fatality and non-fatality) involving an Bunspecified opioid^increased to 8.1% of total opioid cases in 2016, compared to 6.5, 4.1, and 0.6% in 2015, 2014, and 2013, respectively [2, 7, 8] . In addition, two fatalities were attributed to unspecified opioids as single agents and one to unspecified opioids with cocaine in 2016, in contrast to zero deaths from unspecified opioids in 2014 and 2015 [2, 7] . One possible explanation for the rise in unspecified opioid case reporting may be the difficulty in clinically identifying the specific illicit opioid responsible.
The increase in ToxIC opioid cases (both fatal and nonfatal) in 2016 likewise reflects the national opioid crisis. The percentage of opioid cases vs. total Registry cases increased from 8.8% in 2015 to 9.8% in 2016 [2] . As in 2015, heroin, oxycodone, and methadone were the most commonly reported opioids in 2016, each up slightly from 2015 in terms of absolute numbers and percent of total opioid cases [2] . In addition, several designer opioids-3-methylfentanyl, remifentanil, and U-47700-were reported for the first time in ToxIC in 2016. Of all the opioids reported, two decreased notably from 2015 to 2016: buprenorphine, down to 4.2% from 7.5% of opioid cases in 2015, and tramadol, down to 7.8% from 10.5% of opioid cases in 2015 [2] . 
Laundry Detergent Pods
Liquid laundry detergent pods have been responsible for a number of pediatric poisonings, both mild and severe, in the USA and several European countries, with young children (i.e., age 0-6 years) disproportionately affected [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . In response to public concern and warnings from the US Consumer Product Safety Commission (CPSC), the American Association of Poison Control Centers (AAPCC), and others, several manufacturers (including P&G, responsible for 80% of the share of the US market) recently agreed to adopt a new safety standard for detergent pod packaging released in 2015 by the American Society of Testing and Materials [25] [26] [27] [28] . Among other things, the standard mandates using opaque instead of clear packaging, adding a bittering agent to the outer membrane, and other features designed to make the pods less attractive to young children [27, 28] .
Although it is unclear whether or not these changes have succeeded in reducing accidental pediatric ingestions, the early numbers are promising. Detergent pod cases reported annually to AAPCC/US poison control centers declined in [26] . Similarly, since the first detergent pod cases were recorded in the ToxIC Registry in 2012, cases involving young children (i.e., age 0-6 years) have declined both in absolute and relative terms, from a peak in 2013 of 32 cases (4.2% of total cases age 0-6 years) to 9 cases (1.4% of total cases age 0-6 years) in 2016 [8, 9] . In 2016, one ToxIC pediatric case involved a 9-year-old female, and all others were age ≤3 years. Among the pediatric cases, central nervous system depression was reported in four, bradypnea with respiratory depression in one, corrosive injury in two, and reactive airway disease and aspiration pneumonitis requiring intubation in one, with no fatalities reported. It is unclear what effect the new safety standards have had on cases of laundry pod exposures as reported to the Registry, though the continued decline is reassuring.
Adverse Drug Reactions
Lithium has been the most commonly reported ADR agent in ToxIC each year since the field was added in 2014 and was responsible for 11.9% of ADRs in 2016 [2, 7] . This is out of proportion to its overall Registry representation, with only 176 total cases involving lithium reported in 2016. Quetiapine was one of the most common medications involved in ADRs in 2014 and 2015 but did not top the list in 2016, despite being the most commonly reported antipsychotic drug in the Registry [2, 7] . Instead, haloperidol and olanzapine were both among the top 10 ADR-related drugs in 2016, together comprising 7.2% of reported ADRs. Digoxin was the second most commonly reported ADR-related drug this year, despite being infrequently reported in the Registry overall; 43.2% of digoxin cases in 2016 were categorized as ADRs. In 2016 acetaminophen was also one of the most common agents associated with an ADR, although ADRs were only implicated in 0.9% of all acetaminophen cases in the Registry. In five ADR cases the outcomes were fatal, with the strength of the association between the exposure and clinical presentation reported as probable in all five. Among those five ADRs which had a fatal outcome, the ages ranged from 41 to 76. Two of the cases were also recorded as medication errors.
Limitations
ToxIC contains data as reported by medical toxicologists treating patients at the bedside, with reliable associations between clinical signs and symptoms and the toxic agents responsible. Nonetheless, there are some inherent limitations of the Registry from a descriptive epidemiological perspective, as well as structural and data quality limitations that continue to be addressed through an ongoing quality improvement process. One inherent limitation is that the central case inclusion criterion-consultation by a medical toxicologistlikely creates a reporting bias toward more severe or unusual cases. At the site level, bias may be introduced through either the decision to consult and/or by the reporting medical toxicologist her/himself. We attempt to control this bias through written agreements with the participating sites that every case seen by the medical toxicologist will be logged in the Registry. In addition, ToxIC cases represent those presenting for clinical care, thus are likely biased toward severe/unusual exposures compared to sources such as Poison Control Centers. Another inherent bias is the limited number of medical toxicologists in practice, currently estimated to be only a few hundred nationwide. This restricts the Registry cases to those geographic areas with actively practicing medical toxicologists, who have also agreed to ToxIC's participation rules and guidelines. Indeed, the Registry has grown to include sites from 22 states across the country and thus includes a large, diverse collection of cases and practice patterns, which for some agents/exposures may reasonably be considered representative of national trends. But some areas, such as the southeastern and western USA, are underrepresented in ToxIC compared to others, so trends unique to those areas may not be fully reflected in the database. Limited case entries required that two of the international sites not be included in the Registry in 2016, thus limiting the scope of data collected largely to the USA. In 2014, centralized, ongoing quality assurance procedures were initiated, designed to improve the accuracy of data entry and coding, and to minimize the number of missing entries. Year 2016 is also the second complete year of data collection since several data fields were made mandatory including include race, ethnicity, reason for encounter, presence of suicidal intent, signs and symptoms, treatments, other interventions, and fatalities. Prior to this, it was unknown if items left blank were not applicable or simply not recorded. This improvement has nearly eliminated missing responses in these fields, and future research will benefit from the improved clarity of responses.
Despite the fact that the race and ethnicity questions were made mandatory in 2014, approximately one quarter of cases were reported as unknown/uncertain race and/or ethnicity in both 2015 and 2016. These data are not self-reported and may not routinely be reflected in patient charts, requiring the examiner to specifically recall this information. For some participating clinicians, race and ethnicity may not be a routine part of their information gathering. Additionally, with the Registry's potential bias toward more complicated and critically ill exposures, there may be a larger than expected number of patients unable to report this information to the examiner. Quality improvement efforts continue, with a goal of minimizing the number of cases reported as unknown or uncertain race and ethnicity.
Significant physical examination findings, vital sign abnormalities, supportive interventions, and some clinical laboratory data are collected; however, the severity of illness is not directly recorded. Although the completeness of the clinical data has improved since creating the mandatory fields, there remain some cases, such as fatalities, where multiple interventions might be expected but are not recorded. In addition, the timeline of events and cause of death are not described. Multiple agents may be reported, but unless free text fields are used, it may be unclear to what degree each agent contributed.
Additional limitations include those inherent in any database. Each case is unique, and some details may be too complicated to be adequately described in a series of programmed data fields. Free text fields are available to enter additional information at the medical toxicologist's discretion, but the free text fields are not easily searchable and must be reviewed manually.
Conclusions
Since its inception in 2010, the ToxIC Registry has continued to grow and is the only database of its kind logging all cases encountered by participating medical toxicologists. While agent frequencies may vary from year to year, and new trends may emerge, overall the most common exposures, toxidromes, clinical abnormalities, and antidotes recorded in ToxIC represent the routine practice of the subspecialty of medical toxicology. It is thus potentially useful as an instructional tool for trainees in toxicology, valuable for toxicosurveillance and research, and as a resource for the practice of medical toxicologists. 
